GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd (SHSE:688336) » Definitions » Debt-to-Revenue

Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Debt-to-Revenue : 0.04 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Sunshine Guojian Pharmaceutical (Shanghai) Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Sunshine Guojian Pharmaceutical (Shanghai) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥50 Mil. Sunshine Guojian Pharmaceutical (Shanghai) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥0 Mil. Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized Revenue for the quarter that ended in Mar. 2025 was ¥1,244 Mil. Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.04.


Sunshine Guojian Pharmaceutical (Shanghai) Co Debt-to-Revenue Historical Data

The historical data trend for Sunshine Guojian Pharmaceutical (Shanghai) Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Guojian Pharmaceutical (Shanghai) Co Debt-to-Revenue Chart

Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
Trend Dec12 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.18 0.05 0.04

Sunshine Guojian Pharmaceutical (Shanghai) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.04 0.05 0.04

Competitive Comparison of Sunshine Guojian Pharmaceutical (Shanghai) Co's Debt-to-Revenue

For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Guojian Pharmaceutical (Shanghai) Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunshine Guojian Pharmaceutical (Shanghai) Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sunshine Guojian Pharmaceutical (Shanghai) Co's Debt-to-Revenue falls into.


;
;

Sunshine Guojian Pharmaceutical (Shanghai) Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Sunshine Guojian Pharmaceutical (Shanghai) Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(50.022 + 0) / 1193.568
=0.04

Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(50.016 + 0) / 1244.476
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.


Sunshine Guojian Pharmaceutical (Shanghai) Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sunshine Guojian Pharmaceutical (Shanghai) Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Traded in Other Exchanges
N/A
Address
No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
Executives
Weng Zhi Bing Core technical personnel
Huang Hao Min Core technical personnel

Sunshine Guojian Pharmaceutical (Shanghai) Co Headlines

No Headlines